These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10947298)

  • 1. Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease.
    Nuijten MJ
    Pharmacoeconomics; 2000 Mar; 17(3):227-36. PubMed ID: 10947298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incorporation of potential confounding variables in Markov models.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic assessment of decision models in Parkinson's disease.
    Siebert U; Bornschein B; Walbert T; Dodel RC
    Value Health; 2004; 7(5):610-26. PubMed ID: 15367256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2002; 20(12):855-67. PubMed ID: 12236807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the burden and mortality of hospitalisation in Parkinson's disease: A cross-sectional analysis of the English Hospital Episodes Statistics database 2009-2013.
    Low V; Ben-Shlomo Y; Coward E; Fletcher S; Walker R; Clarke CE
    Parkinsonism Relat Disord; 2015 May; 21(5):449-54. PubMed ID: 25737205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
    Cooper NJ; Sutton AJ; Abrams KR
    Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.
    Nuijten MJ
    Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A report on the WHO working group on Parkinson's disease.
    Janca A
    Neuroepidemiology; 1999; 18(5):236-40. PubMed ID: 10461048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
    Rubenstein LM; DeLeo A; Chrischilles EA
    Pharmacoeconomics; 2001; 19(7):729-52. PubMed ID: 11548910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic model of Parkinson's disease: implications for slowing progression in the United States.
    Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD
    Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of uncertainty in health economic modelling studies.
    O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
    Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using social exchange theory to understand non-terminal palliative care referral practices for Parkinson's disease patients.
    Prizer LP; Gay JL; Perkins MM; Wilson MG; Emerson KG; Glass AP; Miyasaki JM
    Palliat Med; 2017 Oct; 31(9):861-867. PubMed ID: 28659011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.